Akero Therapeutics Inc

AKRO

NASDAQ. Currency in USD

38.77 -8.18 ( -17.41% )

Real time prices: December 19

Market Cap.
1.81B
Beta (5Y monthly)
-0.88
Price/Earnings
-
EPS (TTM)
-3.36
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
4.05M
1y Target Est.
50.33
Day's Range
35.80
-
41.23
52 Week's Range
7.52
-
48.38

Historical Summary

Performance
EPS growth
Share Buybacks

About Akero Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.akerotx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
34.89M
Employees
34
Address
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Latest news

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022....
By Zacks Investment Research - 13 weeks ago

Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers

Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression...
By Zacks Investment Research - 14 weeks ago

AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen...
By Zacks Investment Research - 14 weeks ago

Are Medical Stocks Lagging  AVEO Pharmaceuticals (AVEO) This Year?
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to...
By Zacks Investment Research - 14 weeks ago

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared...
By Zacks Investment Research - 16 weeks ago

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results...
By Benzinga - 17 weeks ago

Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on...
By Benzinga - 17 weeks ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),...
By GlobeNewswire Inc. - 18 weeks ago